Kalijn F Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree, Anna L de Goede, Annemiek J de Boer, Kevin J H Bos, Tjitske Duiveman-de Boer, Michel A M Olde Nordkamp, Tom G M van Oorschot, Carlijn J Popelier, Jeanne M Pots, Nicole M Scharenborg, Mandy W M M van de Rakt, Valeska de Ruiter, Wilmy S van Meeteren, Michelle M van Rossum, Sandra J Croockewit, Bouke J Koeneman, Jeroen H A Creemers, Inge M N Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A van der Veldt, Dirk J van Grünhagen, Johanna E M Werner, Johannes J Bonenkamp, John B A G Haanen, Marye J Boers-Sonderen, Rutger H T Koornstra, Martijn F Boomsma, Erik H J Aarntzen, Martin Gotthardt, James Nagarajah, Theo J M de Witte, Carl G Figdor, Johannes H W de Wilt, Johannes Textor, Jan Willem B de Groot, Winald R Gerritsen, I Jolanda M de Vries
Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36...
February 23, 2024: Nature Communications